"Developing novel treatments for Dormant Cancers - targeting resistance, metastasis, and relapse."
We are late pre-clinical stage oncology drug development company developing new therapies against cancer. We have a vision of changing cancer treatment, addressing resistance development and patient relapse. Felicitex owns proprietary sets of validated leads: selective and specific small molecule inhibitors as well as companion diagnostic assay.Principals have unique expertise in the dormant cancer pathways, extensive Pharma and business development experience. Felicitex has developed multiple collaboration with leading academic and commercial institutions.
© 2019 by Felicitex Therapeutics, Inc »« 27 Strathmore Road Natick, MA 01760 1-919-213-0025 (p) Click here to Contact Us!